Asked by: Samantha Niblett (Labour - South Derbyshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with Cabinet colleagues on the research and development of femtech solutions; and what assessment he has made of the potential impact of femtech solutions on women's health outcomes.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
While no explicit discussions have been held or assessments made, supporting patients’ equitable access to innovative technologies, and empowering their decision-making in care are key priorities for the Department and NHS England. The National Institute for Health and Care Research (NIHR), the research delivery arm of the Department, has funded and continues to fund research relevant to FemTech. For example, a recent study used new technology to analyse magnetic resonance images using artificial intelligence software to aid the diagnosis of endometriosis. The NIHR welcomes funding applications for research into any aspect of human health, including FemTech solutions.
Asked by: Toby Perkins (Labour - Chesterfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will take steps to implement a heart disease action plan.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
We are committed to ensuring that fewer lives are lost to the biggest killers, such as heart disease, which includes cardiovascular disease (CVD), and stroke. That is why in our Health Mission to build a National Health Service fit for the future, we have committed to reducing deaths from heart disease and strokes by a quarter within ten years.
We are taking steps to reduce heart disease. The NHS Long Term Plan set an aim to prevent up to 150,000 heart attacks, strokes, and dementia cases by 2029, and activity is underway. The NHS Health Check programme, England’s CVD prevention programme, engages over 1.3 million people a year and prevents approximately 500 heart attacks or strokes each year. To improve access and engagement with the NHS Health Check, we are developing a new digital service which people can use at home to understand and act on their CVD risk, providing people with a more flexible, accessible, and convenient service. We are also piloting a new programme to deliver more than 130,000 lifesaving heart health checks in the workplace. These checks can be completed quickly and easily by people at work across 48 local authorities until 31 March 2025.
Asked by: Mark Sewards (Labour - Leeds South West and Morley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to support people diagnosed with Ehlers-Danlos syndrome.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to improving the lives of those living with rare diseases, such as Ehlers-Danlos Syndrome (EDS). The UK Rare Diseases Framework sets out four priorities collaboratively developed with the rare disease community. These include better coordination of care and improving access to specialist care, treatments, and drugs. We remain committed to delivering under the framework, and will publish an annual England action plan in 2025 which will report on progress.
NHS England commissions some specialist services for patients with EDS, currently delivered by two centres in England, the London North West University Healthcare Trust and the Sheffield Children’s NHS Foundation Trust. The Complex EDS service provides diagnosis and advice to referrers on the treatment and management of complex cases.
Asked by: Dan Norris (Labour - North East Somerset and Hanham)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help reduce the waiting list for people seeking treatment to relieve the symptoms of Parkinson's disease.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
We recognise that patients have been let down whilst they wait for the care they need, including within neurology services. The NHS Constitution sets out that 92% of patients should wait no longer than 18 weeks from referral to treatment. We will deliver an extra 40,000 operations, scans, and appointments per week, as a first step in our commitment to ensuring patients can expect to be treated within 18 weeks.
At the national level, there are a number of initiatives supporting service improvement and better care for patients with Parkinson’s disease, including the Getting It Right First Time Programme for Neurology and the RightCare Progressive Neurological Conditions Toolkit. These initiatives aim to reduce variation and deliver care more equitably across the country.
The National Institute for Health and Care Excellence (NICE) guidance, Parkinson’s disease: Diagnosis and management in primary and secondary care, updated in 2017, sets out best practice for clinicians in the identification and treatment of Parkinson’s, in line with the latest available evidence. The guidance states that if Parkinson's is suspected, people should be referred quickly to a specialist with expertise in the differential diagnosis of this condition.
We expect integrated care boards (ICBs) and National Health Service trusts to have due regard to relevant NICE guidelines. It is the responsibility of ICBs to make available appropriate provision to meet the health and care needs of their local population, in line with these NICE guidelines.
Once diagnosed, and with a management strategy in place, most people with Parkinson’s can be cared for through routine access to primary and secondary care. NHS England commissions the specialised elements of Parkinson’s care that patients may receive from 27 specialised neurological treatment centres across England. Within specialised centres, neurological multidisciplinary teams ensure patients can access a range of health professionals, including Parkinson’s disease nurses, psychologists, and allied health professionals such as dieticians and speech and language therapists, and that they can receive specialised treatment and support, according to their needs.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what treatments are (a) available and (b) due to become available in the next 12 months on the NHS for people who have experienced adverse side effects to Covid-19 vaccines.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
In the very rare event where an individual may have suffered a severe adverse reaction to a COVID-19 vaccine, care and treatment will be best met and managed by National Health Service local specialist services, augmented as appropriate by national specialist advice. Individuals will be treated and managed through existing healthcare services, with any treatment dependent on the individuals’ clinical needs.
Asked by: Cat Smith (Labour - Lancaster and Wyre)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to announce the future funding for drug and alcohol treatment provision as part of the Drugs Strategy in time for services to avoid commencing redundancy consultations; and if he will change future treatment funding announcement cycles to give local authorities more time to (a) plan and (b) commission such services.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government supports investment in drug and alcohol treatment and recovery services, to ensure that those people with a substance use need get appropriate help and support. In addition to the Public Health Grant, the Department has allocated local authorities a further £267 million in 2024/25 to improve the quality and capacity of drug and alcohol treatment and recovery. This is alongside £105 million made available by the Department of Health and Social Care, the Department for Work and Pensions, and the Ministry of Housing, Communities and Local Government to improve employment and housing support.
My Rt. Hon. friend, the Chancellor of the Exchequer announced updates to the fiscal framework, and earlier this year launched the Spending Review which has now settled the 2025/26 departmental budgets. She has also made it clear that the Government will conclude a multi-year Spending Review in spring 2025. In future, we anticipate that Spending Reviews will be set every two years to cover a three-year period, including a one-year overlap with the previous Spending Review, helping build in greater certainty and stability over public finances.
Now that the Autumn Budget has been completed, the Department is working to be able to announce future funding allocations for drug and alcohol treatment and recovery systems. We will communicate with the sector about this as soon as we are able to, as we recognise the importance of this information in maintaining delivery and planning for 2025/26.
Asked by: Cat Smith (Labour - Lancaster and Wyre)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he plans to announce (a) whether Drug Strategy funding for drug and alcohol treatment providers will be renewed and at what levels and (b) the length of the funding cycle; and if he will take steps to ensure that local authorities have adequate notice of alcohol and drug treatment funding.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government supports investment in drug and alcohol treatment and recovery services, to ensure that those people with a substance use need get appropriate help and support. In addition to the Public Health Grant, the Department has allocated local authorities a further £267 million in 2024/25 to improve the quality and capacity of drug and alcohol treatment and recovery. This is alongside £105 million made available by the Department of Health and Social Care, the Department for Work and Pensions, and the Ministry of Housing, Communities and Local Government to improve employment and housing support.
My Rt. Hon. friend, the Chancellor of the Exchequer announced updates to the fiscal framework, and earlier this year launched the Spending Review which has now settled the 2025/26 departmental budgets. She has also made it clear that the Government will conclude a multi-year Spending Review in spring 2025. In future, we anticipate that Spending Reviews will be set every two years to cover a three-year period, including a one-year overlap with the previous Spending Review, helping build in greater certainty and stability over public finances.
Now that the Autumn Budget has been completed, the Department is working to be able to announce future funding allocations for drug and alcohol treatment and recovery systems. We will communicate with the sector about this as soon as we are able to, as we recognise the importance of this information in maintaining delivery and planning for 2025/26.
Asked by: James MacCleary (Liberal Democrat - Lewes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to (a) prevent heart disease and stroke, (b) prioritise timely NHS heart care and (c) accelerate research into future treatments and cures.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
We are committed to ensuring that fewer lives are lost to the biggest killers, such as heart disease, which includes cardiovascular diseases (CVD), and stroke.
The NHS Health Check, England’s flagship CVD prevention programme, engages over 1.3 million people each year and prevents approximately 500 heart attacks or strokes. To improve access and engagement to this life saving check, we are developing a digital NHS Health Check, a service which people can use at home to understand and act on their CVD risk, providing people with a more flexible, accessible, and convenient service. We are also piloting a new programme to deliver more than 130,000 lifesaving heart health checks in workplaces across the country.
The NHS Long Term Plan (NHS LTP) is committed to improving the care and outcomes for people with CVD through enhanced diagnostic support in the community, better personalised planning, and increased access to disease-specific rehabilitation. NHS England’s stroke priorities include rapid diagnosis and increased access to time-dependent acute stroke care, as well as facilitating ambulance service use of pre-hospital telemedicine, and supporting access to the use of artificial intelligence decision support tools for brain imaging.
Asked by: Freddie van Mierlo (Liberal Democrat - Henley and Thame)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his Department’s policies of the recommendation from the French health authority that the RSV vaccine should be provided to (a) 75-80 and (b) over 80 year olds.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
The Joint Committee on Vaccination and Immunisation (JCVI) is the United Kingdom’s expert committee that advises the government on immunisation programmes.
In line with JCVI advice, the respiratory syncytial virus (RSV) vaccination programme for adults turning 75 years old began on 1 September 2024 in England alongside a one-off catch-up programme to rapidly vaccinate all those already aged between 75 and 79 years old. The JCVI considered that there was less certainty about how well the vaccine works in people aged 80 years old and older, as there were not enough people of this age in the clinical trials to be able to see if the vaccines are protective in this age band.
Whilst the JCVI notes what takes place in other countries, its advice is specific to the UK. The JCVI continues to keep evidence under review, including data from clinical trials and real world evidence emerging from immunisation programmes in different countries.
The JCVI recently discussed the RSV programme at their committee meeting on 2nd October 2024. The minutes from this meeting are publicly available at the following link: https://www.gov.uk/government/groups/joint-committee-on-vaccination-and-immunisation
Asked by: Josh Simons (Labour - Makerfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of support for people who experience migraines; and whether he plans to provide additional support.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence’s (NICE) guideline, Headaches: Diagnosis and management of headaches in young people and adults, updated in December 2021, sets out best practice for healthcare professionals in the care, treatment, and support of people who suffer from headaches, including migraines. It aims to improve the recognition and management of headaches and migraines.
At the national level, there are a number of initiatives supporting service improvement and better care for patients with migraines, including the Getting It Right First Time (GIRFT) Programme for Neurology and the RightCare Headache and Migraine Toolkit. The GIRFT Programme published a National Speciality Report, which makes several recommendations in relation to improving recognition and diagnosis of migraines by general practitioners. Additionally, the RightCare Headache and Migraine Toolkit sets out key priorities for improving care for patients with migraines, which includes correct identification and diagnosis of headache disorders.
The Royal College of General Practitioners has developed two e-learning modules about migraines and cluster headaches, which aim to raise awareness amongst primary care clinicians about the different types of migraine and their associated symptoms, and how to differentiate.
Over the last four years, a new class of drugs, calcitonin gene-related peptide (CGRP) inhibitors, has been made available on the National Health Service for the prevention and treatment of episodic and chronic migraines. On 15 May 2024, Atogepant became the latest CGRP inhibitor for which the NICE has published guidance. The NICE recommended Atogepant for use as a preventive medication for the treatment of migraines on the NHS in England.